The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1.
Open Access
- 15 April 1998
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 101 (8) , 1699-1707
- https://doi.org/10.1172/jci2166
Abstract
To identify molecular factors regulating apo A-I production in vivo, we induced in transgenic mice the experimental nephrotic syndrome, which results in elevated levels of HDL cholesterol (HDL-C), plasma apo A-I, and hepatic apo A-I mRNA. Human (h) apo A-I transgenic mice with different length 5' flanking sequences (5.5 or 0.256 kb, the core promoter for hepatic-specific basal expression) were injected with nephrotoxic (NTS) or control serum. With nephrosis, there were comparable (greater than twofold) increases in both lines of HDL-C, h-apo A-I, and hepatic h-apo A-I mRNA, suggesting that cis-acting elements regulating induced apo A-I gene expression were within its core promoter. Hepatic nuclear extracts from control and nephrotic mice footprinted the core promoter similarly, implying that the same elements regulated basal and induced expression. Hepatic mRNA levels for hepatocyte nuclear factor (HNF) 4 and early growth response factor (EGR) 1, trans-acting factors that bind to the core promoter, were measured: HNF4 mRNA was not affected, but that of EGR-1 was elevated approximately fivefold in the nephrotic group. EGR-1 knockout (EGR1-KO) mice or mice expressing EGR-1 were injected with either NTS or control serum. Levels of HDL-C, apo A-I, and hepatic apo A-I mRNA were lowest in nonnephrotic EGR1-KO mice and highest in nephrotic mice expressing EGR-1. Although in EGR1-KO mice HDL-C, apo A-I, and apo A-I mRNA levels also increased after NTS injection, they were approximately half of those in the nephrotic EGR-1-expressing mice. We conclude that in this model, basal and induced apo A-I gene expression in vivo are regulated by the trans-acting factor EGR-1 and require the same cis-acting elements in the core promoter.Keywords
This publication has 42 references indexed in Scilit:
- Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor RORαJournal of Biological Chemistry, 1997
- Utilization of Recombinant Adenovirus and Dominant Negative Mutants to Characterize Hepatocyte Nuclear Factor 4-regulated Apolipoprotein AI and CIII ExpressionJournal of Biological Chemistry, 1997
- Transcriptional Regulation of the Genes Involved in Lipoprotein TransportHypertension, 1996
- Growth and Differentiation Proceeds Normally in Cells Deficient in the Immediate Early Gene NGFI-AJournal of Biological Chemistry, 1995
- Rabbit and rat liver nuclei both contain proteins which bind to the regions controlling apolipoprotein A‐I gene expressionEuropean Journal of Biochemistry, 1993
- Tissue and species differences in bile salt-dependent neutral cholesteryl ester hydrolase activity and gene expression.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat.Journal of Clinical Investigation, 1990
- Regulation of apolipoprotein gene expression and plasma high-density lipoprotein composition in experimental nephrosisBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- The β-globin dominant control region activates homologous and heterologous promoters in a tissue-specific mannerCell, 1989